Tirzepatide FDA Approves Zepbound Supplemental Efficacy Application

The U.S. Food and Drug Administration approved a supplemental application for Zepbound (tirzepatide) on October 18, 2024. The FDA classified the application as an efficacy submission and identified Eli Lilly and Company as the sponsor.

Background

Tirzepatide is identified in the supplied FDA record under the brand name Zepbound. The same drug data also list the aliases Zepbound KwikPen, Mounjaro, and Mounjaro KwikPen. The record provided for this event concerns Zepbound and an application categorized as efficacy.

The supplied data do not specify the disease or patient population connected with the supplemental application. They also do not provide a mechanism of action, dosing information, a new indication, or details of prior approvals. Those details are therefore not reported here.

What happened

FDA’s event record described the action as approval of a supplemental application for Zepbound (tirzepatide), with the application identified as NDA 217806 S-6. The event was categorized as FDA supplemental approval, and its class was listed as efficacy.

The available data do not state whether the action added a new indication, expanded an existing population, changed the label, or addressed another efficacy-related element of the application. No clinical-trial identifier, study design, enrollment total, comparator, endpoint, treatment effect, p-value, confidence interval, or adverse-event result was supplied.

What this means

The approval confirms that FDA took action on Eli Lilly’s supplemental Zepbound application in the efficacy category on October 18, 2024. However, the supplied record alone does not establish the specific clinical claim evaluated or describe how efficacy was demonstrated.

Clinicians, researchers, patient advocates, and editors seeking the exact approved change should consult the FDA application record and any associated prescribing-information or approval documents. The event data support reporting the approval itself, but not a specific efficacy percentage, comparative result, indication, or dosing recommendation.

Source

Source: U.S. Food and Drug Administration, application overview record for NDA 217806, documenting the supplemental efficacy approval associated with NDA217806-SUPPL-6 on October 18, 2024. The source is available through accessdata.fda.gov at accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA217806.